These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 28143835)

  • 1. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
    Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
    Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
    Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
    Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers.
    Barlabé P; Sostoa J; Fajardo CA; Alemany R; Moreno R
    Cancer Gene Ther; 2020 May; 27(5):383-388. PubMed ID: 31204390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
    Arnone CM; Polito VA; Mastronuzzi A; Carai A; Diomedi FC; Antonucci L; Petrilli LL; Vinci M; Ferrari F; Salviato E; Scarsella M; De Stefanis C; Weber G; Quintarelli C; De Angelis B; Brenner MK; Gottschalk S; Hoyos V; Locatelli F; Caruana I; Del Bufalo F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
    Freedman JD; Hagel J; Scott EM; Psallidas I; Gupta A; Spiers L; Miller P; Kanellakis N; Ashfield R; Fisher KD; Duffy MR; Seymour LW
    EMBO Mol Med; 2017 Aug; 9(8):1067-1087. PubMed ID: 28634161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
    Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
    Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
    Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
    Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
    Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
    Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
    Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
    Santos J; Heiniö C; Quixabeira D; Zafar S; Clubb J; Pakola S; Cervera-Carrascon V; Havunen R; Kanerva A; Hemminki A
    Cells; 2021 Apr; 10(5):. PubMed ID: 33922052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
    Tanoue K; Rosewell Shaw A; Watanabe N; Porter C; Rana B; Gottschalk S; Brenner M; Suzuki M
    Cancer Res; 2017 Apr; 77(8):2040-2051. PubMed ID: 28235763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
    Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
    Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.